2026 Q1 -tulosraportti
49 päivää sitten
‧43 min
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 27.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 29.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·3 päivää sittenQuick overview regarding upcoming news to keep an eye on for the rest of the year: Q3: uTREAT® – topline read-out efficacy data in brain cancer (GBM) H2: uTRACE® – preliminary efficacy data ph 2 trial (Curium partnership) Q4: uTRACE® – topline results ph 2 trial (Curium partnership) Q3/Q4: FDA uTreat ph2 application Q3/Q4: Possible partnership announcement on uTreat & Basket trial: From Medwatch article d. 25. Juni -> "We are already experiencing great interest in our platform and technology," says CEO Ulrich Krasilnikoff to MedWatch. He makes no secret of the fact that the company is deliberately preparing for negotiations." + "If (topline) data turns out positive, the plan is to use them as leverage in negotiations with larger partners." https://medwatch.dk/brancher/Medicinal___Biotek/article19426291.ece (article can be accessed via 14-day free subscription): ...have I forgotten other, important triggers:) ?
Fundraising targeted investors. (2 digits millioner USD) Topline uTrace II should trigger a milestone payment Partnership for basket trial uTreat (they will not start it without a partner, with good topline it should not be difficult to find one)
·10.7. · MuokattuAnd just the quick one from copilot Has uTRACE® been used in brain cancer trials?Yes. uTRACE® has been used in clinical studies investigating uPAR expression in glioblastomas. These studies showed that 94 % of glioblastoma patients are uPAR-positive, which is precisely the target uTRACE® binds to. This is documented in Curasight's own data and is used as the basis for the design of the uTREAT trials. uTRACE® is therefore clinically tested in brain tumors, but primarily as a diagnostic tracer, not as a treatment. And this is where the sentence is important.. WHAT YOU SEE IS WHAT YOU TREAT
I think you should have sent your CV and application to the company long ago, so you can just tell them how things are connected?- ·10.7. · MuokattuRemember now, as Andreas Kjær said a long time ago WHAT YOU SEE IS WHAT YOU TREAT.. A very important sentence... What has already been shown to work in utrace will also work in I utreat.. (The cancer is receptive/open)...Yes, that is clearly one of the most important sentences for their case and communication approach. But, really, calm down. It's about making complex material less complex - it's not quite that simple in practice and there are quite a few intermediate calculations in the process towards an ultimate goal with approved, successful treatments. Enjoy the summer, log off and don't stress about the upcoming fall, which I believe is in store here in July-August. The forum here will be wild in a bit, I think, when people can't understand why it has to go down several kroner further.
·10.7.Arthkri ... there is summer holiday, and normally (Trump) without the big fluctuations!!
·9.7.Why is everyone suddenly so quiet in here? Is anyone afraid that it will go wrong?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
49 päivää sitten
‧43 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·3 päivää sittenQuick overview regarding upcoming news to keep an eye on for the rest of the year: Q3: uTREAT® – topline read-out efficacy data in brain cancer (GBM) H2: uTRACE® – preliminary efficacy data ph 2 trial (Curium partnership) Q4: uTRACE® – topline results ph 2 trial (Curium partnership) Q3/Q4: FDA uTreat ph2 application Q3/Q4: Possible partnership announcement on uTreat & Basket trial: From Medwatch article d. 25. Juni -> "We are already experiencing great interest in our platform and technology," says CEO Ulrich Krasilnikoff to MedWatch. He makes no secret of the fact that the company is deliberately preparing for negotiations." + "If (topline) data turns out positive, the plan is to use them as leverage in negotiations with larger partners." https://medwatch.dk/brancher/Medicinal___Biotek/article19426291.ece (article can be accessed via 14-day free subscription): ...have I forgotten other, important triggers:) ?Fundraising targeted investors. (2 digits millioner USD) Topline uTrace II should trigger a milestone payment Partnership for basket trial uTreat (they will not start it without a partner, with good topline it should not be difficult to find one)
- ·10.7. · MuokattuAnd just the quick one from copilot Has uTRACE® been used in brain cancer trials?Yes. uTRACE® has been used in clinical studies investigating uPAR expression in glioblastomas. These studies showed that 94 % of glioblastoma patients are uPAR-positive, which is precisely the target uTRACE® binds to. This is documented in Curasight's own data and is used as the basis for the design of the uTREAT trials. uTRACE® is therefore clinically tested in brain tumors, but primarily as a diagnostic tracer, not as a treatment. And this is where the sentence is important.. WHAT YOU SEE IS WHAT YOU TREATI think you should have sent your CV and application to the company long ago, so you can just tell them how things are connected?
- ·10.7. · MuokattuRemember now, as Andreas Kjær said a long time ago WHAT YOU SEE IS WHAT YOU TREAT.. A very important sentence... What has already been shown to work in utrace will also work in I utreat.. (The cancer is receptive/open)...Yes, that is clearly one of the most important sentences for their case and communication approach. But, really, calm down. It's about making complex material less complex - it's not quite that simple in practice and there are quite a few intermediate calculations in the process towards an ultimate goal with approved, successful treatments. Enjoy the summer, log off and don't stress about the upcoming fall, which I believe is in store here in July-August. The forum here will be wild in a bit, I think, when people can't understand why it has to go down several kroner further.
- ·10.7.Arthkri ... there is summer holiday, and normally (Trump) without the big fluctuations!!
- ·9.7.Why is everyone suddenly so quiet in here? Is anyone afraid that it will go wrong?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 27.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 29.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 |
2026 Q1 -tulosraportti
49 päivää sitten
‧43 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 27.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 29.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·3 päivää sittenQuick overview regarding upcoming news to keep an eye on for the rest of the year: Q3: uTREAT® – topline read-out efficacy data in brain cancer (GBM) H2: uTRACE® – preliminary efficacy data ph 2 trial (Curium partnership) Q4: uTRACE® – topline results ph 2 trial (Curium partnership) Q3/Q4: FDA uTreat ph2 application Q3/Q4: Possible partnership announcement on uTreat & Basket trial: From Medwatch article d. 25. Juni -> "We are already experiencing great interest in our platform and technology," says CEO Ulrich Krasilnikoff to MedWatch. He makes no secret of the fact that the company is deliberately preparing for negotiations." + "If (topline) data turns out positive, the plan is to use them as leverage in negotiations with larger partners." https://medwatch.dk/brancher/Medicinal___Biotek/article19426291.ece (article can be accessed via 14-day free subscription): ...have I forgotten other, important triggers:) ?Fundraising targeted investors. (2 digits millioner USD) Topline uTrace II should trigger a milestone payment Partnership for basket trial uTreat (they will not start it without a partner, with good topline it should not be difficult to find one)
- ·10.7. · MuokattuAnd just the quick one from copilot Has uTRACE® been used in brain cancer trials?Yes. uTRACE® has been used in clinical studies investigating uPAR expression in glioblastomas. These studies showed that 94 % of glioblastoma patients are uPAR-positive, which is precisely the target uTRACE® binds to. This is documented in Curasight's own data and is used as the basis for the design of the uTREAT trials. uTRACE® is therefore clinically tested in brain tumors, but primarily as a diagnostic tracer, not as a treatment. And this is where the sentence is important.. WHAT YOU SEE IS WHAT YOU TREATI think you should have sent your CV and application to the company long ago, so you can just tell them how things are connected?
- ·10.7. · MuokattuRemember now, as Andreas Kjær said a long time ago WHAT YOU SEE IS WHAT YOU TREAT.. A very important sentence... What has already been shown to work in utrace will also work in I utreat.. (The cancer is receptive/open)...Yes, that is clearly one of the most important sentences for their case and communication approach. But, really, calm down. It's about making complex material less complex - it's not quite that simple in practice and there are quite a few intermediate calculations in the process towards an ultimate goal with approved, successful treatments. Enjoy the summer, log off and don't stress about the upcoming fall, which I believe is in store here in July-August. The forum here will be wild in a bit, I think, when people can't understand why it has to go down several kroner further.
- ·10.7.Arthkri ... there is summer holiday, and normally (Trump) without the big fluctuations!!
- ·9.7.Why is everyone suddenly so quiet in here? Is anyone afraid that it will go wrong?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt